Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Begins Subjecting Liquid Medicines To Retail Price Caps

This article was originally published in PharmAsia News

Executive Summary

All liquid medicines in India, including antibiotics and multivitamins, are to be subjected to price caps for the first time by the National Pharmaceutical Pricing Authority. Medicines in liquid form account for 15 percent of the retail market in India, and producers include all domestic drug makers. The drug-pricing authority has notified makers of the maximum retail prices set for 16 medicines that use any of 74 bulk drugs subject to price controls. The NPPA is preventing companies from avoiding the caps by covering all possible pack sizes up to 500ml. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts